Please assess the completion status of the following clinical trial:

Trial Title: A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Individuals eligible for enrollment in this study were female and male individuals who had been shown to be healthy and who were:~1. 11-18 years of age inclusive who had given their written consent/assent and if applicable, whose parents or legal guardians had given written informed consent at the time of enrollment;~   * Available for all visits and telephone calls scheduled for the study;~  * In good health as determined by:~     * Medical history~    * Physical assessment~    * Clinical judgment of the investigator~2. Had been properly vaccinated against diphtheria, tetanus, and pertussis per local regulations;~3. Subjects who were current with childhood DTP-containing vaccinations per local guidelines. Any previous vaccinations containing DTP must have been received at least 5 years before study enrollment and no prior adolescent vaccinations (11-18 years of age) containing DTP vaccines were allowed.~4. For female subjects, who had a negative urine pregnancy test.~5. Any female subject who is sexually active committed to practice appropriate birth control.~Exclusion Criteria:~Individuals not eligible to be enrolled in the study were those:~1. Who were unwilling to give their written assent / consent~2. Who were breastfeeding~3. Who was, and/or whose parents or legal guardians were perceived to be unreliable or unavailable for the duration of the study period~4. Who had previous confirmed or suspected disease caused by N. meningitidis~5. Who had household contact with and/or intimate exposure to an individual with culture-proven N. meningitidis infection within 60 days prior to enrollment~6. Who had previously been immunized with a meningococcal vaccine or vaccine containing meningococcal antigen(s) (licensed or investigational). (Exception: Receipt of OMP-containing Hib vaccines was permitted)~7. Who had received prior human papillomavirus (HPV) vaccine~8. Who had received investigational agents or vaccines within 30 days prior to enrollment or who expected to receive an investigational agent or vaccine prior to completion of the study~9. Who had received live licensed vaccines within 30 days and inactive vaccine within 15 days prior to enrollment or for whom receipt of a licensed vaccine is anticipated during the study period.~   (Exception: Influenza vaccine could be administered up to 15 days prior to each study immunization and no less than 15 days after each study vaccination)~10. Who had experienced, within the 7 days prior to enrollment, significant acute or chronic infection (for example requiring systemic antibiotic treatment or antiviral therapy) or had experienced fever (defined as body temperature ≥ 38°C) within 3 days prior to enrollment~11. Who had any serious acute, chronic or progressive disease such as~    * History of cancer~   * Complicated diabetes mellitus~   * Advanced arteriosclerotic disease~   * Autoimmune disease~   * HIV infection or AIDS~   * Blood dyscrasias~   * Congestive heart failure~   * Renal failure~   * Severe malnutrition (Note: Subjects with mild asthma were eligible for enrollment. Subjects with moderate or severe asthma requiring routine use of inhaled or systemic corticosteroids were not eligible for enrollment)~12. Who had epilepsy, any progressive neurological disease or history of Guillain-Barre syndrome~13. Who had a history of anaphylaxis, serious vaccine reactions, or allergy to any vaccine component, including latex allergy~14. Who had a known or suspected impairment/alteration of immune function, either congenital or acquired or resulting from (for example):~    * Receipt of immunosuppressive therapy within 30 days prior to enrollment (systemic corticosteroids administered for more than 5 days, or in a daily dose \> 1 mg/kg/day prednisone or equivalent during any of 30 days prior to enrollment, or cancer chemotherapy)~   * Receipt of immunostimulants~   * Receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within 90 days prior to enrollment and for the full length of the study~15. Who were known to have a bleeding diathesis, or any condition that may be associated with a prolonged bleeding time;~16. Who have Down's syndrome or other known cytogenic disorders;~17. Who and/or whose families were planning to leave the area of the study site before the end of the study period;~18. Who had any condition that, in the opinion of the investigator, might interfere with the evaluation of the study objectives.~19. Who were relatives of the study personnel.

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Placebo + Tdap + HPV (Type: PLACEBO_COMPARATOR): This group will receive Tdap, HPV and placebo concomitantly for the first vaccination. The second and third doses of HPV vaccine will be administered to all subjects 2 and 6 months after the first dose. All subjects will have serum samples collected at Visit 1 (baseline), Visit 2 (31 days) and Visit 5 (7 months after visit 1) for serology testing.
- MenACWY-CRM + Tdap + HPV (Type: EXPERIMENTAL): This group will receive Tdap, HPV and MenACWY-CRM concomitantly. The second and third doses of HPV vaccine will be administered to this group 2 and 6 months after the first dose. All subjects will have serum samples collected at Visit 1 (baseline), Visit 2 (31 days) and Visit 5 (7 months after visit 1) for serology testing.

Based on this trial design, predict the completion outcome and termination type (if applicable).